Identification

Name
Colesevelam
Accession Number
DB00930  (APRD00883)
Type
Small Molecule
Groups
Approved
Description

Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol.

Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Colesevelam hydrochlorideP4SG24WI5Q182815-44-7VTAKZNRDSPNOAU-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CholestagelTablet, film coated625 mgOralGenzyme Europe Bv2004-03-10Not applicableEu
CholestagelTablet, film coated625 mgOralGenzyme Europe Bv2004-03-10Not applicableEu
CholestagelTablet, film coated625 mgOralGenzyme Europe Bv2004-03-10Not applicableEu
CholestagelTablet, film coated625 mgOralGenzyme Europe Bv2004-03-10Not applicableEu
Colesevelam hydrochlorideTablet, film coated625 mg/1OralOhm Laboratories, Inc.2018-05-23Not applicableUs
Colesevelam hydrochloridePowder, for suspension3.75 g/1OralOhm Laboratories, Inc.2018-07-17Not applicableUs
LodalisPowder, for suspension3.75 gOralValeant Canada Lp Valeant Canada S.E.C.2015-04-02Not applicableCanada
LodalisTablet625 mgOralValeant Canada Lp Valeant Canada S.E.C.2012-02-06Not applicableCanada
WelcholTablet, film coated625 mg/1OralCarilion Materials Management2000-09-01Not applicableUs65597 0701 18 nlmimage10 ad1dd6fe
WelcholFor suspension3.75 g/1OralDaiichi Sankyo, Inc.2010-01-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Colesevelam HydrochlorideTablet, coated625 mg/1OralImpax Generics2018-05-17Not applicableUs
Colesevelam HydrochloridePowder, for suspension3.75 g/1OralGlenmark Pharmaceuticals Inc.,Usa2018-07-17Not applicableUs
Colesevelam HydrochlorideTablet, coated625 mg/1OralAv Kare, Inc.2018-06-18Not applicableUs
Colesevelam HydrochloridePowder, for suspension1.875 g/1OralGlenmark Pharmaceuticals Inc.,Usa2018-07-17Not applicableUs
Colesevelam HydrochlorideTablet, film coated625 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2018-05-18Not applicableUs
Colesevelam HydrochlorideTablet, coated625 mg/1OralAmerincan Health Packaging2018-07-15Not applicableUs
International/Other Brands
CholestaGel (Genzyme)
Categories
UNII
1XU104G55N
CAS number
182815-43-6
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

For use, alone or in combination with an HMG-CoA reductase inhibitor, as adjunctive therapy to diet and exercise for the reduction of elevated LDL cholesterol in patients with primary hypercholesterolemia (Fredrickson Type IIa).

Associated Conditions
Pharmacodynamics

Colesevelam is a high capacity bile-acid binding molecule. Colesevelam binds to bile acids in the intestine which reduces the amount of bile acids that are returned to the liver via enterohepatic circulation. Clinical studies have demonstrated that elevated levels of total cholesterol (total-C), LDL-C, and apolipoprotein B (Apo B, a protein associated with LDL-C) are associated with an increased risk of atherosclerosis in humans. Similarly, decreased levels of high-density lipoprotein cholesterol (HDL-C) are associated with the development of atherosclerosis. Epidemiological investigations have established that cardiovascular morbidity and mortality vary directly with the levels of total-C and LDL-C, and inversely with the level of HDL-C. The combination of colesevelam and an HMG-CoA reductase inhibitor is effective in further lowering serum total-C and LDL-C levels beyond that achieved by either agent alone.

Mechanism of action

Colesevelam is a non-absorbed, lipid-lowering polymer that binds bile acids in the intestine, impeding their reabsorption. As the bile acid pool becomes depleted, the hepatic enzyme, cholesterol 7-(alpha)-hydroxylase, is upregulated, which increases the conversion of cholesterol to bile acids. This causes an increased demand for cholesterol in the liver cells, resulting in the dual effect of increasing transcription and activity of the cholesterol biosynthetic enzyme, hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase, and increasing the number of hepatic low-density lipoprotein (LDL) receptors. These compensatory effects result in increased clearance of LDL cholesterol (LDL-C) from the blood, resulting in decreased serum LDL-C levels. Serum triglyceride levels may increase or remain unchanged. The end result is increased clearance of LDL-cholesterol from the blood with decreased serum LDL-cholesterol.

TargetActionsOrganism
ABile acids
binder
Human
Absorption

Not hydrolyzed by digestive enzymes and is not absorbed.

Volume of distribution
Not Available
Protein binding

Not applicable (not hydrolyzed by digestive enzymes and not absorbed).

Metabolism

Not applicable (not hydrolyzed by digestive enzymes and not absorbed).

Route of elimination

Excretion: In 16 healthy volunteers, an average of 0.05% of administered radioactivity from a single 14C-labeled colesevelam hydrochloride dose was excreted in the urine.

Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose may include eye irritation, constipation, abdominal cramps, nausea, vomiting, diarrhea, and hypersensitivity. However, as colesevelam is not absorbed, the risk of systemic toxicity is low. Doses in excess of 4.5 g per day have not been tested.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneColesevelam can cause a decrease in the absorption of (4R)-limonene resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
16-BromoepiandrosteroneColesevelam can cause a decrease in the absorption of 16-Bromoepiandrosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
19-norandrostenedioneColesevelam can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
5-androstenedioneColesevelam can cause a decrease in the absorption of 5-androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
AceclofenacColesevelam can cause a decrease in the absorption of Aceclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AcemetacinColesevelam can cause a decrease in the absorption of Acemetacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
AcenocoumarolColesevelam can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AcetyldigitoxinColesevelam can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetyldigoxinColesevelam can cause a decrease in the absorption of Acetyldigoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Acetylsalicylic acidColesevelam can cause a decrease in the absorption of Acetylsalicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AdapaleneColesevelam can cause a decrease in the absorption of Adapalene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclofenacColesevelam can cause a decrease in the absorption of Alclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
AlclometasoneColesevelam can cause a decrease in the absorption of Alclometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AldosteroneColesevelam can cause a decrease in the absorption of Aldosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
AlfacalcidolThe serum concentration of Alfacalcidol can be decreased when it is combined with Colesevelam.Approved, Nutraceutical
AlminoprofenColesevelam can cause a decrease in the absorption of Alminoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium clofibrateColesevelam can cause a decrease in the absorption of Aluminium clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AmcinonideColesevelam can cause a decrease in the absorption of Amcinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmiodaroneThe excretion of Amiodarone can be increased when combined with Colesevelam.Approved, Investigational
AndrographolideColesevelam can cause a decrease in the absorption of Andrographolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
AndrostenedioneColesevelam can cause a decrease in the absorption of Androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
AnecortaveColesevelam can cause a decrease in the absorption of Anecortave resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
anecortave acetateColesevelam can cause a decrease in the absorption of anecortave acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
AnisodamineColesevelam can cause a decrease in the absorption of Anisodamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
AntipyrineColesevelam can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ApocyninColesevelam can cause a decrease in the absorption of Apocynin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
ApremilastColesevelam can cause a decrease in the absorption of Apremilast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtamestaneColesevelam can cause a decrease in the absorption of Atamestane resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
AtorvastatinColesevelam can cause a decrease in the absorption of Atorvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AzapropazoneColesevelam can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
AzelastineColesevelam can cause a decrease in the absorption of Azelastine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AzosemideColesevelam can cause a decrease in the absorption of Azosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BalsalazideColesevelam can cause a decrease in the absorption of Balsalazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
BendazacColesevelam can cause a decrease in the absorption of Bendazac resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BendroflumethiazideColesevelam can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BenorilateColesevelam can cause a decrease in the absorption of Benorilate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BenoxaprofenColesevelam can cause a decrease in the absorption of Benoxaprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
BenzthiazideColesevelam can cause a decrease in the absorption of Benzthiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BenzydamineColesevelam can cause a decrease in the absorption of Benzydamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BetamethasoneColesevelam can cause a decrease in the absorption of Betamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
BevoniumColesevelam can cause a decrease in the absorption of Bevonium resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BezafibrateColesevelam can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
BromfenacColesevelam can cause a decrease in the absorption of Bromfenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BucillamineColesevelam can cause a decrease in the absorption of Bucillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BufexamacColesevelam can cause a decrease in the absorption of Bufexamac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
BumadizoneColesevelam can cause a decrease in the absorption of Bumadizone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BumetanideColesevelam can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CalcidiolThe serum concentration of Calcidiol can be decreased when it is combined with Colesevelam.Approved, Nutraceutical
CalcipotriolThe serum concentration of Calcipotriol can be decreased when it is combined with Colesevelam.Approved
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Colesevelam.Approved, Nutraceutical
Carbaspirin calciumColesevelam can cause a decrease in the absorption of Carbaspirin calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
CarprofenColesevelam can cause a decrease in the absorption of Carprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved, Withdrawn
CastanospermineColesevelam can cause a decrease in the absorption of Castanospermine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CelecoxibColesevelam can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CerivastatinColesevelam can cause a decrease in the absorption of Cerivastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Colesevelam.Approved
ChlormadinoneThe serum concentration of Chlormadinone can be decreased when it is combined with Colesevelam.Experimental
ChloroquineColesevelam can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlorothiazideColesevelam can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlortetracyclineColesevelam can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlorthalidoneColesevelam can cause a decrease in the absorption of Chlorthalidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Colesevelam.Approved, Nutraceutical
Cholic AcidColesevelam can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateColesevelam can cause a decrease in the absorption of Choline magnesium trisalicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideColesevelam can cause a decrease in the absorption of Ciclesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CiprofibrateColesevelam can cause a decrease in the absorption of Ciprofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClobetasolColesevelam can cause a decrease in the absorption of Clobetasol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Clobetasol propionateColesevelam can cause a decrease in the absorption of Clobetasol propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClobetasoneColesevelam can cause a decrease in the absorption of Clobetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClocortoloneColesevelam can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClofibrateColesevelam can cause a decrease in the absorption of Clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClofibrideColesevelam can cause a decrease in the absorption of Clofibride resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ClonixinColesevelam can cause a decrease in the absorption of Clonixin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClorindioneColesevelam can cause a decrease in the absorption of Clorindione resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Cortexolone 17α-propionateColesevelam can cause a decrease in the absorption of Cortexolone 17α-propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
CorticosteroneColesevelam can cause a decrease in the absorption of Corticosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Cortisone acetateColesevelam can cause a decrease in the absorption of Cortisone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CurcuminColesevelam can cause a decrease in the absorption of Curcumin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CyclopenthiazideColesevelam can cause a decrease in the absorption of Cyclopenthiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Colesevelam.Approved, Investigational, Vet Approved
CymarinColesevelam can cause a decrease in the absorption of Cymarin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Cyproterone acetateThe serum concentration of Cyproterone acetate can be decreased when it is combined with Colesevelam.Approved, Investigational
DeferasiroxThe serum concentration of Deferasirox can be decreased when it is combined with Colesevelam.Approved, Investigational
DeflazacortColesevelam can cause a decrease in the absorption of Deflazacort resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DemeclocyclineColesevelam can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DeslanosideColesevelam can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Colesevelam.Approved
DesonideColesevelam can cause a decrease in the absorption of Desonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DesoximetasoneColesevelam can cause a decrease in the absorption of Desoximetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Desoxycorticosterone acetateColesevelam can cause a decrease in the absorption of Desoxycorticosterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Desoxycorticosterone PivalateColesevelam can cause a decrease in the absorption of Desoxycorticosterone Pivalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Vet Approved
Dexamethasone isonicotinateColesevelam can cause a decrease in the absorption of Dexamethasone isonicotinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
DiclofenacColesevelam can cause a decrease in the absorption of Diclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
DicoumarolColesevelam can cause a decrease in the absorption of Dicoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Colesevelam.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Colesevelam.Approved, Investigational
DifenpiramideColesevelam can cause a decrease in the absorption of Difenpiramide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DiflorasoneColesevelam can cause a decrease in the absorption of Diflorasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiflunisalColesevelam can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DifluocortoloneColesevelam can cause a decrease in the absorption of Difluocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
DifluprednateColesevelam can cause a decrease in the absorption of Difluprednate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DigitoxinColesevelam can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DigoxinColesevelam can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Digoxin Immune Fab (Ovine)Colesevelam can cause a decrease in the absorption of Digoxin Immune Fab (Ovine) resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DihydrotachysterolThe serum concentration of Dihydrotachysterol can be decreased when it is combined with Colesevelam.Approved
DiphenadioneColesevelam can cause a decrease in the absorption of Diphenadione resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DoxercalciferolThe serum concentration of Doxercalciferol can be decreased when it is combined with Colesevelam.Approved
DoxycyclineColesevelam can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Colesevelam.Approved
DroxicamColesevelam can cause a decrease in the absorption of Droxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
DuvelisibColesevelam can cause a decrease in the absorption of Duvelisib resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
E-6201Colesevelam can cause a decrease in the absorption of E-6201 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
EpirizoleColesevelam can cause a decrease in the absorption of Epirizole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EpitizideColesevelam can cause a decrease in the absorption of Epitizide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
EquileninColesevelam can cause a decrease in the absorption of Equilenin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
EquilinColesevelam can cause a decrease in the absorption of Equilin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Colesevelam.Approved, Nutraceutical
EstradiolColesevelam can cause a decrease in the absorption of Estradiol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Colesevelam.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Colesevelam.Approved, Investigational, Vet Approved
EstroneColesevelam can cause a decrease in the absorption of Estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Estrone sulfateColesevelam can cause a decrease in the absorption of Estrone sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Etacrynic acidColesevelam can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EtanerceptColesevelam can cause a decrease in the absorption of Etanercept resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EthenzamideColesevelam can cause a decrease in the absorption of Ethenzamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Colesevelam.Approved
Ethyl biscoumacetateColesevelam can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Colesevelam.Approved
EtodolacColesevelam can cause a decrease in the absorption of Etodolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EtofenamateColesevelam can cause a decrease in the absorption of Etofenamate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EtofibrateColesevelam can cause a decrease in the absorption of Etofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Colesevelam.Approved, Investigational
EtoricoxibColesevelam can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Evening primrose oilColesevelam can cause a decrease in the absorption of Evening primrose oil resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational, Nutraceutical
ExisulindColesevelam can cause a decrease in the absorption of Exisulind resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
EzetimibeColesevelam can cause a decrease in the absorption of Ezetimibe resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FelbinacColesevelam can cause a decrease in the absorption of Felbinac resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FenbufenColesevelam can cause a decrease in the absorption of Fenbufen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FenofibrateColesevelam can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Fenofibric acidColesevelam can cause a decrease in the absorption of Fenofibric acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FenoprofenColesevelam can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FentiazacColesevelam can cause a decrease in the absorption of Fentiazac resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FeprazoneColesevelam can cause a decrease in the absorption of Feprazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferulic acidColesevelam can cause a decrease in the absorption of Ferulic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FloctafenineColesevelam can cause a decrease in the absorption of Floctafenine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
FluasteroneColesevelam can cause a decrease in the absorption of Fluasterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
FludrocortisoneColesevelam can cause a decrease in the absorption of Fludrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FluindioneColesevelam can cause a decrease in the absorption of Fluindione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FlumethasoneColesevelam can cause a decrease in the absorption of Flumethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
FlunisolideColesevelam can cause a decrease in the absorption of Flunisolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FlunixinColesevelam can cause a decrease in the absorption of Flunixin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
FlunoxaprofenColesevelam can cause a decrease in the absorption of Flunoxaprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Fluocinolone AcetonideColesevelam can cause a decrease in the absorption of Fluocinolone Acetonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
FluocinonideColesevelam can cause a decrease in the absorption of Fluocinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FluocortoloneColesevelam can cause a decrease in the absorption of Fluocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
FluorometholoneColesevelam can cause a decrease in the absorption of Fluorometholone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FluprednideneColesevelam can cause a decrease in the absorption of Fluprednidene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
FluprednisoloneColesevelam can cause a decrease in the absorption of Fluprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlurandrenolideColesevelam can cause a decrease in the absorption of Flurandrenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlurbiprofenColesevelam can cause a decrease in the absorption of Flurbiprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FluticasoneColesevelam can cause a decrease in the absorption of Fluticasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
Fluticasone furoateColesevelam can cause a decrease in the absorption of Fluticasone furoate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluvastatinColesevelam can cause a decrease in the absorption of Fluvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FormestaneColesevelam can cause a decrease in the absorption of Formestane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
FurosemideColesevelam can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
GemfibrozilColesevelam can cause a decrease in the absorption of Gemfibrozil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Colesevelam.Approved, Investigational
GestrinoneThe serum concentration of Gestrinone can be decreased when it is combined with Colesevelam.Approved
GitoformateColesevelam can cause a decrease in the absorption of Gitoformate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
GlimepirideColesevelam can cause a decrease in the absorption of Glimepiride resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Colesevelam.Approved, Investigational
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Colesevelam.Approved
GuacetisalColesevelam can cause a decrease in the absorption of Guacetisal resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
HalcinonideColesevelam can cause a decrease in the absorption of Halcinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HE3286Colesevelam can cause a decrease in the absorption of HE3286 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
HigenamineColesevelam can cause a decrease in the absorption of Higenamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
HydrochlorothiazideColesevelam can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
HydroflumethiazideColesevelam can cause a decrease in the absorption of Hydroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Colesevelam.Approved, Investigational
IbuprofenColesevelam can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IbuproxamColesevelam can cause a decrease in the absorption of Ibuproxam resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
IcatibantColesevelam can cause a decrease in the absorption of Icatibant resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Imidazole salicylateColesevelam can cause a decrease in the absorption of Imidazole salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
IndapamideColesevelam can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IndobufenColesevelam can cause a decrease in the absorption of Indobufen resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
IndomethacinColesevelam can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IndoprofenColesevelam can cause a decrease in the absorption of Indoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
IsoxicamColesevelam can cause a decrease in the absorption of Isoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
IstaroximeColesevelam can cause a decrease in the absorption of Istaroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
KebuzoneColesevelam can cause a decrease in the absorption of Kebuzone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
KetoprofenColesevelam can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
KetorolacColesevelam can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Lanatoside CColesevelam can cause a decrease in the absorption of Lanatoside C resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
LeflunomideThe serum concentration of the active metabolites of Leflunomide can be reduced when Leflunomide is used in combination with Colesevelam resulting in a loss in efficacy.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Colesevelam.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Colesevelam.Approved
LiothyronineThe serum concentration of Liothyronine can be decreased when it is combined with Colesevelam.Approved, Vet Approved
LiotrixThe serum concentration of Liotrix can be decreased when it is combined with Colesevelam.Approved
LipegfilgrastimColesevelam may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
LisofyllineColesevelam can cause a decrease in the absorption of Lisofylline resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
LomitapideColesevelam can cause a decrease in the absorption of Lomitapide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LonazolacColesevelam can cause a decrease in the absorption of Lonazolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
LornoxicamColesevelam can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LoteprednolColesevelam can cause a decrease in the absorption of Loteprednol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LovastatinColesevelam can cause a decrease in the absorption of Lovastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LoxoprofenColesevelam can cause a decrease in the absorption of Loxoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LumiracoxibColesevelam can cause a decrease in the absorption of Lumiracoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Colesevelam.Approved, Investigational
Magnesium salicylateColesevelam can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolColesevelam can cause a decrease in the absorption of Masoprocol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ME-609Colesevelam can cause a decrease in the absorption of ME-609 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Meclofenamic acidColesevelam can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Colesevelam.Approved, Investigational
MedrysoneColesevelam can cause a decrease in the absorption of Medrysone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Mefenamic acidColesevelam can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Megestrol acetateThe serum concentration of Megestrol acetate can be decreased when it is combined with Colesevelam.Approved, Investigational, Vet Approved
MelengestrolColesevelam can cause a decrease in the absorption of Melengestrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
MeloxicamColesevelam can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
MesalazineColesevelam can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Colesevelam.Approved
MetamizoleColesevelam can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
MethotrexateColesevelam can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethyclothiazideColesevelam can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MetildigoxinColesevelam can cause a decrease in the absorption of Metildigoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MetolazoneColesevelam can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MevastatinColesevelam can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MinocyclineColesevelam can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MizoribineColesevelam can cause a decrease in the absorption of Mizoribine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
MofebutazoneColesevelam can cause a decrease in the absorption of Mofebutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MometasoneColesevelam can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Mycophenolate mofetilColesevelam can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Colesevelam.Approved
NabumetoneColesevelam can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NafamostatColesevelam can cause a decrease in the absorption of Nafamostat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NaftifineColesevelam can cause a decrease in the absorption of Naftifine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NaproxenColesevelam can cause a decrease in the absorption of Naproxen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
NCX 1022Colesevelam can cause a decrease in the absorption of NCX 1022 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NepafenacColesevelam can cause a decrease in the absorption of Nepafenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NiacinColesevelam can cause a decrease in the absorption of Niacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Nutraceutical
NifenazoneColesevelam can cause a decrease in the absorption of Nifenazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Niflumic AcidColesevelam can cause a decrease in the absorption of Niflumic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NimesulideColesevelam can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
NitroaspirinColesevelam can cause a decrease in the absorption of Nitroaspirin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Nomegestrol acetateThe serum concentration of Nomegestrol acetate can be decreased when it is combined with Colesevelam.Approved, Investigational
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Colesevelam.Approved, Investigational
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Colesevelam.Approved
NorethynodrelThe serum concentration of Norethynodrel can be decreased when it is combined with Colesevelam.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Colesevelam.Approved, Investigational
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Colesevelam.Approved
NorgestrienoneThe serum concentration of Norgestrienone can be decreased when it is combined with Colesevelam.Experimental
OleandrinColesevelam can cause a decrease in the absorption of Oleandrin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Oleoyl-estroneColesevelam can cause a decrease in the absorption of Oleoyl-estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
OlmesartanThe serum concentration of Olmesartan can be decreased when it is combined with Colesevelam.Approved, Investigational
OlopatadineColesevelam can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OlsalazineColesevelam can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OrgoteinColesevelam can cause a decrease in the absorption of Orgotein resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
OuabainColesevelam can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OxaprozinColesevelam can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OxyphenbutazoneColesevelam can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
OxytetracyclineColesevelam can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
PalmidrolColesevelam can cause a decrease in the absorption of Palmidrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Nutraceutical
ParamethasoneColesevelam can cause a decrease in the absorption of Paramethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ParecoxibColesevelam can cause a decrease in the absorption of Parecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam.Approved, Investigational
ParthenolideColesevelam can cause a decrease in the absorption of Parthenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PeruvosideColesevelam can cause a decrease in the absorption of Peruvoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PhenindioneColesevelam can cause a decrease in the absorption of Phenindione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PhenprocoumonColesevelam can cause a decrease in the absorption of Phenprocoumon resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PhenylbutazoneColesevelam can cause a decrease in the absorption of Phenylbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Colesevelam.Approved, Vet Approved
PimecrolimusColesevelam can cause a decrease in the absorption of Pimecrolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PiretanideColesevelam can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PirfenidoneColesevelam can cause a decrease in the absorption of Pirfenidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PiroxicamColesevelam can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PirprofenColesevelam can cause a decrease in the absorption of Pirprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PitavastatinColesevelam can cause a decrease in the absorption of Pitavastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PolythiazideColesevelam can cause a decrease in the absorption of Polythiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PranoprofenColesevelam can cause a decrease in the absorption of Pranoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
PrasteroneColesevelam can cause a decrease in the absorption of Prasterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Nutraceutical
Prasterone sulfateColesevelam can cause a decrease in the absorption of Prasterone sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PravastatinColesevelam can cause a decrease in the absorption of Pravastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PrednicarbateColesevelam can cause a decrease in the absorption of Prednicarbate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PrednisoneColesevelam can cause a decrease in the absorption of Prednisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PregnenoloneColesevelam can cause a decrease in the absorption of Pregnenolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
ProglumetacinColesevelam can cause a decrease in the absorption of Proglumetacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PropacetamolColesevelam can cause a decrease in the absorption of Propacetamol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropranololColesevelam can cause a decrease in the absorption of Propranolol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropyphenazoneColesevelam can cause a decrease in the absorption of Propyphenazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ProquazoneColesevelam can cause a decrease in the absorption of Proquazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ProscillaridinColesevelam can cause a decrease in the absorption of Proscillaridin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PTC299Colesevelam can cause a decrease in the absorption of PTC299 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
QuinethazoneColesevelam can cause a decrease in the absorption of Quinethazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
QuingestanolThe serum concentration of Quingestanol can be decreased when it is combined with Colesevelam.Experimental
RaloxifeneColesevelam can cause a decrease in the absorption of Raloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ResveratrolColesevelam can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
RimexoloneColesevelam can cause a decrease in the absorption of Rimexolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RofecoxibColesevelam can cause a decrease in the absorption of Rofecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
RonifibrateColesevelam can cause a decrease in the absorption of Ronifibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
RosuvastatinColesevelam can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SalicylamideColesevelam can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Salicylic acidColesevelam can cause a decrease in the absorption of Salicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
SalsalateColesevelam can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SemapimodColesevelam can cause a decrease in the absorption of Semapimod resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
SeratrodastColesevelam can cause a decrease in the absorption of Seratrodast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SerrapeptaseColesevelam can cause a decrease in the absorption of Serrapeptase resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
SimfibrateColesevelam can cause a decrease in the absorption of Simfibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SimvastatinColesevelam can cause a decrease in the absorption of Simvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501Colesevelam can cause a decrease in the absorption of SRT501 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
SulfasalazineColesevelam can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulindacColesevelam can cause a decrease in the absorption of Sulindac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SuprofenColesevelam can cause a decrease in the absorption of Suprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
SuxibuzoneColesevelam can cause a decrease in the absorption of Suxibuzone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
TarenflurbilColesevelam can cause a decrease in the absorption of Tarenflurbil resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
TenidapColesevelam can cause a decrease in the absorption of Tenidap resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
TenoxicamColesevelam can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TepoxalinColesevelam can cause a decrease in the absorption of Tepoxalin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
TeriflunomideThe serum concentration of Teriflunomide can be decreased when it is combined with Colesevelam.Approved
TetracyclineColesevelam can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Thyroid, porcineThe serum concentration of Thyroid, porcine can be decreased when it is combined with Colesevelam.Approved
Tiaprofenic acidColesevelam can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TinoridineColesevelam can cause a decrease in the absorption of Tinoridine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
TioclomarolColesevelam can cause a decrease in the absorption of Tioclomarol resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
TixocortolColesevelam can cause a decrease in the absorption of Tixocortol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Tolfenamic AcidColesevelam can cause a decrease in the absorption of Tolfenamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TolmetinColesevelam can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TorasemideColesevelam can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TriamcinoloneColesevelam can cause a decrease in the absorption of Triamcinolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TribenosideColesevelam can cause a decrease in the absorption of Tribenoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
TrichlormethiazideColesevelam can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TriptolideColesevelam can cause a decrease in the absorption of Triptolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Trolamine salicylateColesevelam can cause a decrease in the absorption of Trolamine salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Colesevelam.Approved
UlobetasolColesevelam can cause a decrease in the absorption of Ulobetasol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ursodeoxycholic acidThe serum concentration of Ursodeoxycholic acid can be decreased when it is combined with Colesevelam.Approved, Investigational
ValdecoxibColesevelam can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
VancomycinThe therapeutic efficacy of Vancomycin can be decreased when used in combination with Colesevelam.Approved
WarfarinColesevelam can cause a decrease in the absorption of Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ZaltoprofenColesevelam can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ZileutonColesevelam can cause a decrease in the absorption of Zileuton resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
ZomepiracColesevelam can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Food Interactions
  • Drink liberally.
  • Take with a meal.

References

General References
Not Available
External Links
PubChem Substance
46505437
PharmGKB
PA449095
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Colesevelam
ATC Codes
C10AC04 — Colesevelam
AHFS Codes
  • 24:06.04 — Bile Acid Sequestrants
FDA label
Download (130 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
2CompletedTreatmentDiarrhea / Irritable Bowel Syndrome (IBS)1
2CompletedTreatmentType 2 Diabetes Mellitus2
2RecruitingOtherBile Acid Malabsorption / Chronic Functional Diarrhea / Diarrhoea Predominant Irritable Bowel Syndrome1
2RecruitingSupportive CareMultiple Myeloma (MM)1
2Unknown StatusTreatmentNonalcoholic Steatohepatitis1
2, 3CompletedTreatmentChronic Liver Diseases (CLD)1
2, 3CompletedTreatmentType 2 Diabetes Mellitus1
3CompletedTreatmentHigh Blood Cholesterol Level / Pre-Diabetic / Type 2 Diabetes Mellitus1
3CompletedTreatmentHyperlipidemias / Type 2 Diabetes Mellitus1
3CompletedTreatmentImpaired Fasting Glucose (IFG) / Pre-Diabetic1
3CompletedTreatmentType 2 Diabetes Mellitus6
3RecruitingTreatmentBile Acid Malabsorption / Incontinence, Fecal1
4Active Not RecruitingOtherAtherosclerosis / Carotid Artery Diseases / Coronary Artery Disease1
4CompletedBasic ScienceType 2 Diabetes Mellitus2
4CompletedPreventionDyslipidemias / Hyperglycemias / Hyperlipidemias1
4CompletedTreatmentDiarrhoea Predominant Irritable Bowel Syndrome1
4CompletedTreatmentDyslipidemia (Fredrickson Type Ⅱa)1
4CompletedTreatmentDyslipidemias / Hyperlipidemias1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHigh Blood Cholesterol Level3
4CompletedTreatmentHigh Blood Cholesterol Level / Hyperlipidemia, Familial Combined1
4RecruitingBasic ScienceBileacid Malabsorption1
4RecruitingTreatmentObesity, Severe2
4RecruitingTreatmentType 2 Diabetes Mellitus2
4TerminatedTreatmentBile Acid Malabsorption / Crohns Disease1
Not AvailableCompletedNot AvailableImpaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus1
Not AvailableCompletedBasic ScienceBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
Not AvailableCompletedBasic ScienceDiabetes Mellitus (DM)1
Not AvailableCompletedBasic ScienceTo Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion1
Not AvailableCompletedTreatmentDiabetes, Diabetes Mellitus Type 1 / Hyperlipidemias1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableNot Yet RecruitingBasic ScienceHomozygous Sitosterolemia1

Pharmacoeconomics

Manufacturers
  • Daiichi sankyo inc
Packagers
  • Daiichi Sankyo
  • Patheon Inc.
  • Physicians Total Care Inc.
  • Quality Care
  • Resource Optimization and Innovation LLC
  • Southwood Pharmaceuticals
Dosage forms
FormRouteStrength
Tablet, film coatedOral625 mg
Powder, for suspensionOral1.875 g/1
Powder, for suspensionOral3.75 g/1
Tablet, coatedOral625 mg/1
Powder, for suspensionOral3.75 g
TabletOral625 mg
For suspensionOral1.875 g/1
For suspensionOral3.75 g/1
Tablet, film coatedOral625 mg/1
Prices
Unit descriptionCostUnit
Welchol 625 mg tablet1.96USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5679717No1994-04-292014-04-29Us
US7229613Yes2002-10-172022-10-17Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsolubleNot Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

1. Bile acids
Kind
Group
Organism
Human
Pharmacological action
Yes
Actions
Binder
References
  1. Levy P, Jellinger PS: The potential role of colesevelam in the management of prediabetes and type 2 diabetes mellitus. Postgrad Med. 2010 May;122(3Suppl):1-8. doi: 10.3810/pgm.2010.05.2168. [PubMed:20581432]
  2. Staels B: A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus. Postgrad Med. 2009 May;121(3 Suppl 1):25-30. doi: 10.3810/pgm.2009.05.suppl53.290. [PubMed:19494475]
  3. Corsini A, Windler E, Farnier M: Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. Eur J Cardiovasc Prev Rehabil. 2009 Feb;16(1):1-9. doi: 10.1097/HJR.0b013e32831215db. [PubMed:19237992]
  4. Steinmetz KL, Schonder KS: Colesevelam: potential uses for the newest bile resin. Cardiovasc Drug Rev. 2005 Spring;23(1):15-30. [PubMed:15867945]
  5. Melian EB, Plosker GL: Colesevelam. Am J Cardiovasc Drugs. 2001;1(2):141-6; discussion 147-8. [PubMed:14728043]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 04:32